Daniel Bertholet

Daniel Bertholet is an Investment Director in the Life Sciences practice at Endeavour Vision, with a focus on medtech investments. Daniel has invested in PneumRx, Symetis, CeQur, Nfocus (sold to Covidien), Endoart (sold to Allergan), Thommen Medical (exited), Neocutis (sold to Merz Pharma), Novalar Pharmaceuticals (exited) and Kuros Biosurgery. He also participated in investments and/or follow-on investments in Native Networks (sold to Alcatel), eProject/Daptiv (exited), Paion (IPO), Nexx Systems (sold to Tokyo Electron) and Novimmune. Prior to his venture capital career, Daniel was the co-founder and CFO of a technology start-up and has invested as a business angel/private investor in private companies for over 15 years in Europe and the US. Daniel started his career as a consultant in country risk assessment for Business Environment Risk Intelligence (BERI) in the US and Switzerland. Daniel is a member of the Medtech Task Force of the European Venture Capital Association (EVCA) and has been on the Selection Committee of the Medtech Summits of the European Techtour in 2008, 2010, 2012, 2013 and on the Steering Committee of the OneMedForum conferences in the USA. Daniel has been asked to speak at industry events in US and Europe. Daniel holds an MBA with honours from the Institut d’Etudes Politiques in Paris and a MA in International Political Economy from the American University in Washington DC. Daniel is personally committed to support vulnerable children in Sub-Saharan Africa. He lives in Geneva with his wife and their three children.